HLA-A and uveal melanoma: In a currently active phase II clinical trial, tebentafusp is evaluated against an investigator’s choice of therapy (Systemic Dacarbazine, Ipilimumab, or Pembrolizumab) in HLA-A*0201 positive patients with uveal melanoma with no prior systemic or liver-directed chemo-, radio- or immune-therapy administration (NCT03070392).